Pressmeddelanden
Lipigon Pharmaceuticals announces collaboration with Singapore lung health initiative TARIPH and Shenzhen Institutes of Advanced Technology to study a potential novel treatment for COVID-19
Lipigon Pharmaceuticals AB ("Lipigon"), today announced that the company has entered into a collaboration agreement with The Academic Respiratory Initiative for Pulmonary Health (TARIPH) at Nanyang Technological University, Singapore ("NTU Singapore") and Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (SIAT). The parties will collaborate on a potential novel treatment for Acute Respiratory Distress Syndrome (ARDS), a common and lethal co-morbidity of pneumonia caused by SARS-CoV-2 pandemic and other infectious lung disorders.
"This is a strategically important collaboration that allows Lipigon to test its drug candidates for potential use in treatment in Covid-19 and other infectious lung diseases. It is a great opportunity for us to work with leading experts in this area" explains CEO and co-founder Dr. Stefan K Nilsson.
Lipigon,TARIPH and SIAT will collaborate in the validation of antisense oligonucleotide (ASO) drug candidates targeting angiopoietin-like 4 (ANGPTL4). As part of TARIPH, Associate Professor Nguan Soon Tan's research group at NTU's Lee Kong Chian School of Medicine has shown in several publications that ANGPTL4 plays an important role in lung injury, as it was among the most significantly upregulated genes in the 1918 Spanish flu and 2009 H1N1 swine flu pandemics.
Lipigon has developed ASO drug candidates targeting ANGPTL4 that potentially could treat patients suffering from inflammation-associated lung injury including ARDS. These compounds will be tested by Professor Tan and collaborators, in advanced disease models to provide proof-of-concept for this novel treatment. The compounds have been optimized for efficacy and safety by Lipigon. If proven efficient for treating ARDS these compounds could immediately enter non-clinical safety trials.
"Professor Tan's outstanding research on pulmonary vasculature leakiness and pathological angiogenesis has established ANGPTL4 as a promising drug target. We are extremely happy and fortunate to enter this collaboration which gives our compounds a fast-track to proof of concept in relevant disease models", said Dr. Stefan K. Nilsson. "The SAR-CoV-2 pandemic has pinpointed a significant medical need for novel treatments of all infectious lung diseases. We believe that ANGPTL4 inhibition could make a difference for millions of patients every year".
"Over the last decade, our laboratory findings have suggested that when the expression of ANGPTL4 is suppressed, the duration and severity of lung damage is also reduced, suggesting a strong possibility for faster recovery. I hope our collaboration will lead to significant clinical benefit to patients suffering from lung injury caused by severe pneumonia," said Associate Professor Nguan Soon Tan.
"Our research on ANGPTL4 function in acute lung injury showed potential of ANGPTL4 as a broadspectrum therapy target for pneumonia. We hope our collaboration can provide new tools for clinicians," said Associate Professor Liang Li.
To accelerate the preclinical validation of ANGPTL4 ASO for lung injury, research will be carried out by Professor Tan and his colleagues, including Provost's Chair in Molecular Medicine Assistant Professor Sanjay Chotirmall and Dr Louisa Chan from LKCMedicine, as well as Associate Professor Li Liang from Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.
Press Release September 22nd, 2020
For further information, please contact:
Stefan K Nilsson, CEO Lipigon
Mobile +46 70-578 17 68
Mail: stefan@lipigon.se
About ANGPTL4 and ARDS
Pneumonia kill millions of individuals, most commonly from severe inflammatory response causing damages to the lungs. ANGPTL4 is a gene associated with acute lung injury in both viral and bacterial pneumonia; mainly by promoting pathological angiogenesis and vascular leakage. Infectious lung disease may lead to acute respiratory distress syndrome (ARDS) which is a life-threatening syndrome characterized by acute inflammation in combination with respiratory failure. Patients are commonly treated with oxygen and often mechanical ventilation at intensive care units. Treatment of the infection that causes pneumonia is sometimes not possible, as in the case of SARS-CoV-2 infection and COVID-19, thus there is a great unmet medical need for novel ARDS treatments.
About Lipigon Pharmaceuticals AB
Lipigon develops novel therapeutics for patients with lipid-related disorders. The company is a spin-off from Umeå University, Sweden, based on five decades of lipid research. Our primary focus is orphan lipid disorders and in addition to the ANGPTL antisense program, Lipigon's pipeline includes a program for gene therapy in lipodystrophy, together with Combigene AB (publ) and a small molecule program in collaboration with HitGen (Inc).
Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077 ("Bolaget"), kallas härmed till extra bolagsstämma den 11 januari 2021 klockan 16:00 i Bolagets lokaler på Tvistevägen 48C i Umeå. Inregistrering till stämman börjar klockan 15:30.
Lipigon Pharmaceuticals AB ("Lipigon"), develops novel treatments for patients with lipid-related diseases. The candidate drug (CD) Lipisense is a first-in-class treatment and has shown unique efficacy in experimental disease models. The project now enters pre-clinical safety development.
Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077 ("Bolaget"), kallas härmed till extra bolagsstämma den 4 januari 2021 klockan 10:00 i Bolagets lokaler på Tvistevägen 48C i Umeå. Inregistrering till stämman börjar klockan 9:30.
Vid en extra bolagsstämma den 30 oktober valdes Urban Paulsson till ordinarie styrelseledamot i Lipigon Pharmaceuticals AB. Urban Paulssons affärsjuridiska kompetens innebär en förstärkning av styrelsen och är en viktig komponent för bolagets fortsatta framgångsrika utveckling.
Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077 ("Bolaget"), kallas härmed till extra bolagsstämma den 30/10 2020 klockan 10:00 i bolagets lokaler på Tvistevägen 48C i Umeå. Inregistrering till stämman börjar klockan 9:45.
Lipigon Pharmaceuticals AB ("Lipigon"), tillkännager att bolaget har ingått ett samarbetsavtal med två akademiska institut för att studera bolagets läkemedelskandidat för akut andnödssyndrom som t. ex. kan uppstå till följd av lunginflammation vid covid-19 eller influensa. Avtalet har ingåtts med The Academic Respiratory Initiative for Pulmonary Health (TARIPH) vid Nanyang Technological University, Singapore och Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.
Lipigon Pharmaceutical AB ("Lipigon") meddelar att läkemedelskandidat inom lipodystrofi som utvecklas i samarbete med CombiGene AB ("CombiGene") leder till ny patentansökan. Ansökan har lämnats in vid Storbritanniens patentverk och omfattar de vektorer (virus) som utvecklas inom ramen för projektet. Inlämnandet av ansökan ger en milstolpsbetalning till Lipigon i form av aktier i CombiGene till ett marknadsvärde motsvarande ca. 1,5 miljoner kronor.
Lipigon Pharmaceuticals AB ("Lipigon") har framgångsrikt avslutat en
nyemission av aktier som tillför bolaget närmare 16,7 miljoner kronor. Kapitalet
ska primärt användas för att ta bolagets huvudprogram mot kliniska studier.
Lipigon Pharmaceuticals has successfully closed a new share issue of nearly € 1,6 million. The capital raised will primarily be used to take the most advanced programme of the company towards clinical trials.
Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar läkemedel mot
sjukdomar orsakade av rubbningar i kroppens hantering av fetter, tillkännager
idag att bolaget har ingått ett avtal med HitGen Inc. ("HitGen") som är noterat
på Shanghai-börsen. Bolagen kommer tillsammans att bedriva forskning för att
identifiera och utveckla läkemedelskandidater som påverkar enzymet LPL som
ansvarar för nedbrytning av blodfetter. Målet är att utveckla behandlingar av
hjärt-sjukdom och andra fettrelaterade sjukdomar.
Lipigon enters agreement with HitGen to develop drugs for cardiometabolic diseases Lipigon Pharmaceuticals AB ("Lipigon"), developer of therapeutics for lipid-related diseases, today announced that the company has entered an agreement with STAR listed (Shanghai market) company HitGen Inc. ("HitGen"). The companies will conduct joint research to identify and develop drug candidates that enhance the activity of Lipoprotein Lipase (LPL), with the aim to be used in treatment of lipid disorders and cardiovascular disease.
Lipigon Pharmaceuticals ("Lipigon") tillkännagav idag att bolaget har förvärvat en RNA-läkemedelskandidat baserad på antisens-teknologin som tagits fram med Secarna Pharmceuticals ("Secarna") inom ramen för ett tidigare forskningssamarbete. Lipgion kommer att bedriva fortsatt forskning och utveckling av de förvärvade tillgångarna som inriktar sig på ANGPTL, en genfamilj som bland annat står för reglering av blodfetter. Secarna kommer att erhålla marknadsmässiga betalningar för transaktionen. Parterna har valt att inte offentliggöra närmare detaljer om ersättningen.
Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna Lipigon Pharmaceuticals ("Lipigon") announced that the company has acquired antisense drug candidates jointly generated with Secarna Pharmaceuticals ("Secarna") under a previous research collaboration. Lipigon will continue the research and development of the acquired assets targeting the ANGPTL gene family, and Secarna will receive undisclosed payments customary for such a transaction.
Nyheter
Kommuniké från årsstämma 2023 i Lipigon Pharmaceuticals AB den 25 maj 2023
I dag, den 25 maj 2023, hölls årsstämma i Lipigon Pharmaceuticals AB. Nedan följer en sammanfattning...
Lipigon publicerar delårsrapport för januari-mars 2023
Lipigon Pharmaceuticals AB ("Lipigon") publicerar i dag sin delårsrapport för perioden 1 januari-31 ...
Sista patient färdigbehandlad i Lipigons fas I-studie för behandling av svår hypertriglyceridemi
Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar läkemedel mot sjukdomar orsakade av rubbningar...